Blogs about: Exelixis
Featured Blog
GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184
GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis… more →
Kinase News
Exelixis, Orphan Drug Comretiq, And Business Developments
wrote 3 months ago: On February 21, 2013, Exelixis, a San Francisco biopharmaceutical company developing and commercia … more →
Exelixis, Orphan Drug Cometriq, And The J.P. Morgan Healthcare Conference
wrote 4 months ago: On Wednesday, January 9, 2013, 2:00 PM PST/5:00 PM EST, Exelixis gives a presentation at the J.P. Mo … more →
Which Orphan Drug Companies Are Top-Performing BioTechs In 2012 ?
wrote 5 months ago: Per a December 6, 2012, DailyFinance.com article, Sarepta Therapeutics was identified as one … more →
Exelixis, Orphan Drug Cometriq (Cabozantinib), And The Drug Pipeline: SeekingAlpha.com's Perspective
wrote 5 months ago: On November 29, 2012, the FDA approves Exelixis’ orphan drug Cometriq (Cabozantinib) for the … more →
Diplomat Specialty Pharmacy Gets Deal For Cancer Drug
— 1 comment
wrote 5 months ago: FLINT — Diplomat Specialty Pharmacy and South San Francisco, Calif.-based Exelixis Inc. (Nasda … more →
Diplomat Specialty Pharmacy Selected by Exelixis Inc. As Exclusive Specialty Pharmacy for Cometriq (cabozantinib)
wrote 5 months ago: We at Diplomat Specialty Pharmacy are pleased to share that we have been selected by Exelixis, Inc. … more →
Internet Buzzing About Exelisis’ Orphan Drug Cabozantinib For Medullary Thyroid Cancer
wrote 5 months ago: The Internet is buzzing about Exelisis’ orphan drug Cabozantinib for Medullary Thyroid Cancer … more →
Did The FDA Approve Exelixis’ Orphan Drug Cometriq (Cabozantinib) for Medullary Thyroid Cancer ?
wrote 5 months ago: On November 29, 2012, the FDA approves Exelixis’ orphan drug Cometriq (Cabozantinib) for the … more →
FDA approves clinical use of cabozantinib (but not for prostate cancer, yet)
wrote 5 months ago: The U.S. Food & Drug Administration (FDA) has approved cabozantinib (brand name Cometriq™) for t … more →
Upcoming FDA PDUFA Date For Exelisis’ Orphan Drug Cabozantinib Creates Viral Internet Information Sensation
wrote 5 months ago: On November 26, 2012, the Orphan Druganaut Blog, reports that CafePharma.com, a website for p … more →
Internet Buzzing (November 26, 2012) About Exelisis’ Orphan Drug Cabozantinib For Medullary Thyroid Cancer
wrote 5 months ago: The Internet is buzzing about Exelisis’ orphan drug Cabozantinib for Medullary Thyroid Cancer … more →
Will Exelixis’s Orphan Drug Cabozantinib For Medullary Thyroid Cancer Receive FDA Approval ? – SeekingAlpha.com Perspective
— 1 comment
wrote 5 months ago: SeekingAlpha.com’s November 26, 2012, article titled, “Exelixis’s Cabozantinib Should Receive … more →
Why Is November 29, 2012 Important For Exelixis’ Orphan Drug Cabozantinib For Medullary Thyroid Cancer ?
wrote 5 months ago: Exelixis was scheduled to present orphan drug Cabozantinib before a FDA Oncologic Drug Adviso … more →
ΕΠΙΠΛΑ ΚΑΙ RACK ΓΙΑ ΤΑ ΣΤΕΡΕΟΦΩΝΙΚΑ ΣΑΣ
wrote 7 months ago: Έπιπλα και rack για τα στερεοφωνικά σας. Καλώς ήλθατε στο Blog της EXELIXIS. Για πληροφορίες σχετικά … more →
ΕΠΙΠΛΑ ΚΑΙ RACKS ΓΙΑ ΤΑ ΣΤΕΡΕΟΦΩΝΙΚΑ ΣΑΣ
wrote 7 months ago: ‘Επιπλα και rack για τα στερεοφωνικά σας. Καλώς ήλθατε στο Blog της EXELIXIS. Για πληροφορίες … more →
2012 – 2013 FDA Orphan Drugs Pending Approval Dates
wrote 10 months ago: Here is an updated list of FDA orphan drugs pending approval dates for the rest of 2012 and … more →
Could we see cabozantinib (XL-184) approved some time next year?
wrote 11 months ago: According to a recent media release issued by Exelixis, cabozantinib (also known as XL-184) has show … more →
Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)
wrote 1 year ago: It is now getting close to the middle of May, and that means one thing for biotech investors. The k … more →
Sanofi and Exelixis call off collaboration
wrote 1 year ago: Sanofi and Exelixis have announced that they have decided to end their cooperation on the discovery … more →
